Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

A Common NLRC4 Gene Variant Associates With Inflammation and Pulmonary Function in Human Immunodeficiency Virus and Tuberculosis.

Ravimohan S, Maenetje P, Auld SC, Ncube I, Mlotshwa M, Chase W, Tiemessen CT, Vangu MD, Wallis RS, Churchyard G, Weissman D, Kornfeld H, Bisson GP.

Clin Infect Dis. 2019 Nov 22. pii: ciz898. doi: 10.1093/cid/ciz898. [Epub ahead of print]

PMID:
31751447
2.

Lung injury on antiretroviral therapy in adults with HIV/TB.

Ravimohan S, Auld SC, Maenetje P, Ratsela N, Mlotshwa M, Ncube I, Smith JP, Vangu MD, Sebe M, Kossenkov A, Weissman D, Wallis RS, Churchyard G, Kornfeld H, Bisson GP.

Clin Infect Dis. 2019 Jun 26. pii: ciz560. doi: 10.1093/cid/ciz560. [Epub ahead of print]

PMID:
31242296
3.

Publisher Correction: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2019 Jan;25(1):190. doi: 10.1038/s41591-018-0294-1.

PMID:
30429542
4.

A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis.

Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM.

Nat Med. 2018 Nov;24(11):1708-1715. doi: 10.1038/s41591-018-0224-2. Epub 2018 Nov 5. Erratum in: Nat Med. 2019 Jan;25(1):190.

5.

Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection.

Simmons JD, Stein CM, Seshadri C, Campo M, Alter G, Fortune S, Schurr E, Wallis RS, Churchyard G, Mayanja-Kizza H, Boom WH, Hawn TR.

Nat Rev Immunol. 2018 Sep;18(9):575-589. doi: 10.1038/s41577-018-0025-3. Review.

6.

Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial.

Wallis RS, Good CE, O'Riordan MA, Blumer JL, Jacobs MR, Griffiss JM, Healan A, Salata RA.

PLoS One. 2018 May 2;13(5):e0196756. doi: 10.1371/journal.pone.0196756. eCollection 2018.

7.

Pan-tuberculosis regimens: an argument for.

Wallis RS, Cohen T, Menzies NA, Churchyard G.

Lancet Respir Med. 2018 Apr;6(4):239-240. doi: 10.1016/S2213-2600(18)30096-1. No abstract available.

PMID:
29595501
8.

Application of a whole blood mycobacterial growth inhibition assay to study immunity against Mycobacterium tuberculosis in a high tuberculosis burden population.

Baguma R, Penn-Nicholson A, Smit E, Erasmus M, Day J, Makhethe L, de Kock M, Hughes EJ, van Rooyen M, Pienaar B, Stone L, Hanekom W, Brennan MJ, Wallis RS, Hatherill M, Scriba TJ.

PLoS One. 2017 Sep 8;12(9):e0184563. doi: 10.1371/journal.pone.0184563. eCollection 2017.

9.

Methods for selecting regimen duration to prevent relapse in drug-susceptible and drug-resistant TB.

Davies GR, Wallis RS.

Int J Tuberc Lung Dis. 2016 Dec 1;20(12):13-17. doi: 10.5588/ijtld.16.0231.

PMID:
28240567
10.

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium.

Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.

11.

Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review.

Wallis RS, Zumla A.

Open Forum Infect Dis. 2016 Sep 7;3(3):ofw151. eCollection 2016 Sep. Review.

12.

Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.

Wallis RS.

Eur Respir J. 2016 Nov;48(5):1526-1527. doi: 10.1183/13993003.01207-2016. No abstract available.

13.

Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.

Hoft DF, Blazevic A, Selimovic A, Turan A, Tennant J, Abate G, Fulkerson J, Zak DE, Walker R, McClain B, Sadoff J, Scott J, Shepherd B, Ishmukhamedov J, Hokey DA, Dheenadhayalan V, Shankar S, Amon L, Navarro G, Podyminogin R, Aderem A, Barker L, Brennan M, Wallis RS, Gershon AA, Gershon MD, Steinberg S.

EBioMedicine. 2016 May;7:278-86. doi: 10.1016/j.ebiom.2016.04.010. Epub 2016 Apr 19.

14.

Mathematical Models of Tuberculosis Reactivation and Relapse.

Wallis RS.

Front Microbiol. 2016 May 17;7:669. doi: 10.3389/fmicb.2016.00669. eCollection 2016.

15.

Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.

Harausz EP, Chervenak KA, Good CE, Jacobs MR, Wallis RS, Sanchez-Felix M, Boom WH; TB Research Unit (TBRU) at Case Western Reserve University.

Tuberculosis (Edinb). 2016 May;98:92-6. doi: 10.1016/j.tube.2016.03.002. Epub 2016 Mar 22.

16.

Host-directed therapies for infectious diseases: current status, recent progress, and future prospects.

Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M; Host-Directed Therapies Network consortium.

Lancet Infect Dis. 2016 Apr;16(4):e47-63. doi: 10.1016/S1473-3099(16)00078-5. Review.

PMID:
27036359
17.

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A.

Lancet Infect Dis. 2016 Apr;16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0. Review.

PMID:
27036358
18.

World TB Day 2016: reflections on the global TB emergency.

Zumla A, Schito M, Chakaya J, Marais B, Mwaba P, Migliori GB, Hoelscher M, Maeurer M, Wallis RS.

Lancet Respir Med. 2016 Apr;4(4):249-51. doi: 10.1016/S2213-2600(16)00066-7. Epub 2016 Mar 23. Review. No abstract available.

PMID:
27016869
19.

Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.

Wallis RS, Peppard T.

Clin Infect Dis. 2015 Oct 15;61Suppl 3:S160-3. doi: 10.1093/cid/civ612.

PMID:
26409278
20.

Towards host-directed therapies for tuberculosis.

Zumla A, Maeurer M; Host-Directed Therapies Network, Chakaya J, Hoelscher M, Ntoumi F, Rustomjee R, Vilaplana C, Yeboah-Manu D, Rasolof V, Munderi P, Singh N, Aklillu E, Padayatchi N, Macete E, Kapata N, Mulenga M, Kibiki G, Mfinanga S, Nyirenda T, Maboko L, Garcia-Basteiro A, Rakotosamimanana N, Bates M, Mwaba P, Reither K, Gagneux S, Edwards S, Mfinanga E, Abdulla S, Cardona PJ, Russell JB, Gant V, Noursadeghi M, Elkington P, Bonnet M, Menendez C, Dieye TN, Diarra B, Maiga A, Aseffa A, Parida S, Wejse C, Petersen E, Kaleebu P, Oliver M, Craig G, Corrah T, Tientcheu L, Antonio M, Rao M, McHugh TD, Sheikh A, Ippolito G, Ramjee G, Kaufmann SH, Churchyard G, Steyn A, Grobusch M, Sanne I, Martinson N, Madansein R, Wilkinson RJ, Mayosi B, Schito M, Wallis RS.

Nat Rev Drug Discov. 2015 Aug;14(8):511-2. doi: 10.1038/nrd4696. Epub 2015 Jul 17.

PMID:
26184493
21.

Sputum culture conversion in new TB regimens.

Wallis RS.

Lancet Respir Med. 2015 Jun;3(6):e18-9. doi: 10.1016/S2213-2600(15)00182-4. No abstract available.

PMID:
26065975
22.

Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update.

Wallis RS, Peppard T, Hermann D.

PLoS One. 2015 Apr 29;10(4):e0125403. doi: 10.1371/journal.pone.0125403. eCollection 2015.

23.

Advancing host-directed therapy for tuberculosis.

Wallis RS, Hafner R.

Nat Rev Immunol. 2015 Apr;15(4):255-63. doi: 10.1038/nri3813. Epub 2015 Mar 13. Review.

PMID:
25765201
24.

Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis.

Wallis RS.

Open Forum Infect Dis. 2014 Jun 3;1(1):ofu020. doi: 10.1093/ofid/ofu020. eCollection 2014 Mar.

25.

Sputum culture conversion as a tuberculosis biomarker: a glass half empty or half full?

Wallis RS.

Lancet Respir Med. 2015 Mar;3(3):174-5. doi: 10.1016/S2213-2600(15)00058-2. Epub 2015 Feb 26. No abstract available.

PMID:
25726087
26.

Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis.

Wallis RS, Dawson R, Friedrich SO, Venter A, Paige D, Zhu T, Silvia A, Gobey J, Ellery C, Zhang Y, Eisenach K, Miller P, Diacon AH.

PLoS One. 2014 Apr 14;9(4):e94462. doi: 10.1371/journal.pone.0094462. eCollection 2014.

28.

Lack of a therapeutic role for interferon γ in patients with tuberculosis.

Wallis RS.

J Infect Dis. 2014 Feb 15;209(4):627-8. doi: 10.1093/infdis/jit555. Epub 2013 Oct 16. No abstract available.

PMID:
24133187
29.

Inhibition of mycobacterial growth in vitro following primary but not secondary vaccination with Mycobacterium bovis BCG.

Fletcher HA, Tanner R, Wallis RS, Meyer J, Manjaly ZR, Harris S, Satti I, Silver RF, Hoft D, Kampmann B, Walker KB, Dockrell HM, Fruth U, Barker L, Brennan MJ, McShane H.

Clin Vaccine Immunol. 2013 Nov;20(11):1683-9. doi: 10.1128/CVI.00427-13. Epub 2013 Aug 28.

30.

Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model.

Wallis RS, Wang C, Meyer D, Thomas N.

PLoS One. 2013 Aug 5;8(8):e71116. doi: 10.1371/journal.pone.0071116. Print 2013. Review.

31.

Tuberculosis biomarkers discovery: developments, needs, and challenges.

Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, Schito M, Zumla A.

Lancet Infect Dis. 2013 Apr;13(4):362-72. doi: 10.1016/S1473-3099(13)70034-3. Epub 2013 Mar 24. Review.

PMID:
23531389
32.

Application of a stochastic modeling to assess the evolution of tuberculous and non-tuberculous mycobacterial infection in patients treated with tumor necrosis factor inhibitors.

Agliari E, Asti L, Barra A, Scrivo R, Valesini G, Wallis RS.

PLoS One. 2013;8(1):e55017. doi: 10.1371/journal.pone.0055017. Epub 2013 Jan 28.

33.

Early bactericidal activity of new drug regimens for tuberculosis.

Wallis RS, Nacy C.

Lancet. 2013 Jan 12;381(9861):111-2. doi: 10.1016/S0140-6736(13)60041-0. No abstract available.

PMID:
23312744
34.

Sustainable tuberculosis drug development.

Wallis RS.

Clin Infect Dis. 2013 Jan;56(1):106-13. doi: 10.1093/cid/cis849. Epub 2012 Oct 5.

PMID:
23042970
35.

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother. 2012 Jun;56(6):3114-20. doi: 10.1128/AAC.00384-12. Epub 2012 Apr 2.

36.

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide.

Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF.

PLoS One. 2012;7(1):e30479. doi: 10.1371/journal.pone.0030479. Epub 2012 Jan 18.

37.

SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro.

Reddy VM, Dubuisson T, Einck L, Wallis RS, Jakubiec W, Ladukto L, Campbell S, Nacy CA.

J Antimicrob Chemother. 2012 May;67(5):1163-6. doi: 10.1093/jac/dkr589. Epub 2012 Jan 17.

PMID:
22258923
38.

Biologics and infections: lessons from tumor necrosis factor blocking agents.

Wallis RS.

Infect Dis Clin North Am. 2011 Dec;25(4):895-910. doi: 10.1016/j.idc.2011.08.002. Review.

PMID:
22054762
39.

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis.

Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF.

Antimicrob Agents Chemother. 2011 Feb;55(2):567-74. doi: 10.1128/AAC.01179-10. Epub 2010 Nov 15.

40.

Pulmonary infectious complications of tumor necrosis factor blockade.

Wallis RS, Schluger NW.

Infect Dis Clin North Am. 2010 Sep;24(3):681-92. doi: 10.1016/j.idc.2010.04.010. Review.

PMID:
20674798
41.

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF.

J Infect Dis. 2010 Sep 1;202(5):745-51. doi: 10.1086/655471.

PMID:
20629533
42.

The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement.

Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, Kampmann B, Hellmich B, Groves R, Schreiber S, Wallis RS, Sotgiu G, Schölvinck EH, Goletti D, Zellweger JP, Diel R, Carmona L, Bartalesi F, Ravn P, Bossink A, Duarte R, Erkens C, Clark J, Migliori GB, Lange C.

Eur Respir J. 2010 Nov;36(5):1185-206. doi: 10.1183/09031936.00028510. Epub 2010 Jun 7.

43.

Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice.

Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A.

Lancet. 2010 May 29;375(9729):1920-37. doi: 10.1016/S0140-6736(10)60359-5. Epub 2010 May 18. Review.

PMID:
20488517
44.

Biomarkers for tuberculosis disease activity, cure, and relapse.

Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A.

Lancet Infect Dis. 2010 Feb;10(2):68-9. doi: 10.1016/S1473-3099(10)70003-7. No abstract available.

PMID:
20113972
45.

Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab.

Sitapati AM, Kao CL, Cachay ER, Masoumi H, Wallis RS, Mathews WC.

Clin Infect Dis. 2010 Jan 15;50(2):e7-10. doi: 10.1086/649553.

PMID:
20001539
46.

Biomarkers of disease activity, cure, and relapse in tuberculosis.

Doherty TM, Wallis RS, Zumla A.

Clin Chest Med. 2009 Dec;30(4):783-96, x. doi: 10.1016/j.ccm.2009.08.008. Review.

PMID:
19925967
47.

Advances in immunotherapy for tuberculosis treatment.

Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA.

Clin Chest Med. 2009 Dec;30(4):769-82, ix. doi: 10.1016/j.ccm.2009.08.009. Review.

PMID:
19925966
48.

Infectious complications of tumor necrosis factor blockade.

Wallis RS.

Curr Opin Infect Dis. 2009 Aug;22(4):403-9. doi: 10.1097/QCO.0b013e32832dda55. Review.

PMID:
19491672
49.

Significance of early secreted antigenic target 6-specific T cell depletion after HIV-1 infection.

Wallis RS.

J Infect Dis. 2009 Jul 1;200(1):158; author reply 158-9. doi: 10.1086/599362. No abstract available.

PMID:
19485778
50.

Biomarkers for tuberculosis disease status and diagnosis.

Doherty M, Wallis RS, Zumla A; WHO-Tropical Disease Research/European Commission joint expert consultation group.

Curr Opin Pulm Med. 2009 May;15(3):181-7. Review.

PMID:
19396972

Supplemental Content

Loading ...
Support Center